“Please take notes if you want to, but I’m going to give you an audio-recording of this meeting to take home”

For the majority of newly diagnosed prostate cancer patients, the first meeting with their physician after diagnosis presents them with more information than they are able to assimilate easily … and many patients don’t have the necessary scientific or medical background to understand everything they are being told — even if they hear it all. … READ MORE …

Transrectal biopsy and the increasing risk for procedure-related infection

According to a paper presented at the recent meeting of the European Association of Urology in Madrid, Spain, there seems to be a significant and ongoing rise in the global risk for infections associated with prostate biopsy (and particularly with the transrectal prostate biopsy). … READ MORE …

Does being fit at 50 really NOT lower risk for prostate cancer?

A new study just published in JAMA Oncology appears to suggest that a man’s fitness at age 50 lowers his risk for cardiovascular disease, for colon cancer, and for lung cancer, but actually increases his risk for prostate cancer. One might justifiably wonder whether this makes sense. … READ MORE …

The Prostate Health Index (phi test) and the need for biopsy

It will come as no great surprise to regular readers that your Sitemaster has been less than enthusiastic to date about the potential of the Prostate Health Index or phi test as a tool for assessment of risk for prostate cancer. However, new data is starting to give him slightly greater hope regarding the value of this test. … READ MORE …

After 10 years, risk of prostate cancer-specific mortality lower for high-risk patients

A paper presented at the annual meeting of the European Association of Urology (EAU) suggests that high-risk prostate cancer patients < 60 years of age at the time of radical prostatectomy are more likely to die from their cancer than from other causes during the first 10 years after their surgery. But after that, other causes of death become more likely. … READ MORE …

Vitamin D as a treatment for low-risk prostate cancer? Not based on these data!

A presentation at a meeting of the American Chemical Society in Denver earlier this week suggested the possibility that men who took 4,000 IU of vitamin D every day for 60 days prior to a radical prostatectomy did better than similar men taking a placebo. … READ MORE …

How much time is there to make decisions about treatment for low-risk patients?

In recent years there has been a widely acknowledged, if unconfirmed, assumption that men initially diagnosed with low-risk prostate cancer (clinical stage T1-2a, PSA < 10 ng/ml; and Gleason 3 + 3 = 6 or lower) had plenty of time to come to a good decision about their management options, and did not need to rush such decisions. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,254 other followers